Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Nov;205(5):1746-1750.
doi: 10.1111/bjh.19670. Epub 2024 Jul 23.

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

Barbora Weinbergerová  1 , Jiří Mayer  1 , Tomáš Kabut  1 , Wolfgang R Sperr  2   3 , Jana Števková  4 , Anna Jonášová  5 , Martin Čerňan  6 , Susanne Herndlhofer  2 , Iveta Oravcová  7 , Jiří Šrámek  8 , Jan Novák  9 , Radka Štěpánová  10 , Tomáš Szotkowski  6 , Luboš Drgoňa  7 , Pavel Žák  4 , Peter Valent  2   3
Affiliations
Observational Study

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

Barbora Weinbergerová et al. Br J Haematol. 2024 Nov.

Abstract

Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.

Keywords: acute myeloid leukaemia; antifungal prophylaxis; fungal infection; venetoclax and azacitidine.

PubMed Disclaimer

References

REFERENCES

    1. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–629.
    1. Stemler J, de Jonge N, Skoetz N, Sinkó J, Brüggemann RJ, Busca A, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. Lancet Haematol. 2022;9:e361–e373. https://doi.org/10.1016/S2352‐3026(22)00073‐4
    1. Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, et al. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022;63:1934–1941. https://doi.org/10.1080/10428194.2022.2047964
    1. On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, et al. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol. 2022;197:63–70. https://doi.org/10.1111/bjh.18051
    1. Lee R, Cho SY, Lee DG, Choi H, Park S, Cho BS, et al. Infections of venetoclax‐based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis. Cancers (Basel). 2021;13:6285. https://doi.org/10.3390/cancers13246285

Publication types

MeSH terms

LinkOut - more resources